Table 1.
Clinical and demographic data of multiple sclerosis (MS) and healthy control blood donors.
| Patient | Age (years) | Sex | MS type/therapy | Disease duration (years) | OCB | Relapse 12/24 mo | MRI Brain/Gd | MRI Spine/Gd | EDSS | HLA-DRB1 low resolution |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 33 | F | RRMS Fingolimod |
20 | + | 1/2 | +/- | +/- | 2.0 | 03/03 |
| 2 | 48 | F | RRMS Interferon-b-1a |
13 | + | 0/2 | +/- (↑) | +/- (↑) | 3.5 | 14/15 (DR2) |
| 3 | 25 | M | RRMS Cortisone |
New | + | 1/1 | +/- | +/+ | 1.5 | 11/11 |
| 4 | 45 | F | RRMS None |
New | + | 1/2 | +/- (↑) | +/+ (↑) | 3.0 | 04/16 (DR2) |
| 7 | 35 | M | RRMS Cortisone |
New | – | 1/1 | +/- | -/- | 1.0 | 04/12 |
| 8 | 57 | M | RRMS Interferon-b-1a |
25 | – | 0/0 | +/- | +/- | 4.0 | 07/16 (DR2) |
| 9 | 40 | F | RRMS Interferon-b-1a |
5 | + | 3/5 | +/- | -/- | 4.0 | 15/16 (DR2) |
| 10 | 37 | F | RRMS Fingolimod |
10 | + | 3/3 | +/+(↑) | +/- | 3.5 | 15/16 (DR2) |
| 11 | 30 | F | RRMS Interferon-b-1a |
10 | + | 1/1 | +/± (↑) | +/- (↓) | 2.5 | 04/15 (DR2) |
| 17 | 35 | F | RRMS Fingolimod |
20 | + | 1/0 | +/- (↑) | +/- | 2.0 | 13/13 |
| 18 | 54 | F | OPN | CIS | – | 1/0 | +/- | +/- | 1.0 | ND |
| 22 | 35 | M | RRMS Natalizumab |
18 | + | 0/0 | +/- (↓) | +/- (↓) | 2.5 | 04/16 (DR2) |
| N1 | 23 | F | Healthy | NA | NA | NA | NA | NA | NA | 04/15 (DR2) |
| N2 | 50 | F | Healthy | NA | NA | NA | NA | NA | NA | 01/04 |
Key: EDSS, expanded disability status scale; Gd, gadolinium; OCB, oligoclonal bands in cerebrospinal fluid; OPN, optic neuritis; NA, not applicable; ND, not done; RRMS, relapsing-remitting MS; ↑ ↓, increased or decreased lesion load compared to previous MRI, respectively (MRI performed less than 6 months prior to blood sampling); CIS, clinically isolated syndrome.